6 Biotechnology Stocks to Buy Now

by Portfolio Grader | September 18, 2013 10:45 am

This week, six Biotechnology stocks are improving their overall ratings on Portfolio Grader[1]. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

NeoStem, Inc. (NASDAQ:NBS[2]) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Unicode Decode Error. In Portfolio Grader’s specific subcategories of Earnings Revisions and Sales Growth, NBS also gets A’s. The stock price has risen 8.4% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of NBS stock[3].

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA[4]) boosts its rating from a C to a B this week. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock[5].

The rating of Neurocrine Biosciences, Inc. (NASDAQ:NBIX[6]) moves up this week, rising from a C to a B. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. For more information, get Portfolio Grader’s complete analysis of NBIX stock[7].

This week, Array BioPharma (NASDAQ:ARRY[8]) pushes up from a C to a B rating. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. For more information, get Portfolio Grader’s complete analysis of ARRY stock[9].

This week, Celldex Therapeutics, Inc. (NASDAQ:CLDX[10]) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock[11].

Insmed Incorporated (NASDAQ:INSM[12]) boosts its rating from a C to a B this week. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. For more information, get Portfolio Grader’s complete analysis of INSM stock[13].

Louis Navellier’s proprietary Portfolio Grader[14] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[15].

Source URL: https://investorplace.com/2013/09/6-biotechnology-stocks-to-buy-now-nbs-aria-nbix/

---